Table 1.
Response to immunotherapy in the ICI treatment cohort
| Total (n = 36) | NMP = 0/1 (n = 16) | NMP ≥ 2 (n = 20) | P value | |
|---|---|---|---|---|
| CR | 5 (13.9%) | 5 (31.3%) | 0 (0.0%) | |
| PR | 12 (33.3%) | 7 (43.8%) | 5 (25.0%) | |
| Non-CR/non-PD | 5 (13.9%) | 2 (12.5%) | 3 (15.0%) | |
| Stable disease | 3 (8.3%) | 1 (6.3%) | 2 (10.0%) | |
| PD | 9 (25.0%) | 1 (6.3%) | 8 (40.0%) | |
| No assessmenta | 2 (5.6%) | 0 (0%) | 2 (10.0%) | |
| ORR in modified population (n = 31)b | 54.8% | 85.7% | 29.4% | 0.002 |
| 4-month PFS rate (n = 32)c | 62.5% | 93.3% | 35.3% | 0.001 |
Abbreviations: CR complete response, ORR objective response rate, PD progressive disease, PFS progressive-free disease, PR partial response
aNo assessment represents the patients who had a baseline assessment but no post-baseline assessment at the time of the data cutoff date, due to death before the first post-baseline radiologic imaging assessment
bModified population represents the patients with evaluable target lesion
cFour patients who have been followed up for less than 4 months and have not yet progressed were excluded from the analysis of 4-month PFS rate